Lessons from breast cancer trials of HER2-kinase inhibitors
Mené sur 508 patientes atteintes d'un cancer métastatique du sein HER2+ ayant progressé après un traitement au trastuzumab, cet essai international compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'afatinib et du trastuzumab, en combinaison avec la vinorelbine
The clinical development of the HER2-specific monoclonal antibody trastuzumab is an oncology success story. Adding trastuzumab to chemotherapy markedly improves survival for patients with both early and advanced HER2-positive breast cancer. Despite this success, trastuzumab regimens are not effective in all patients, and in patients with metastatic disease, tumors inevitably progress. However, trastuzumab provides benefit even after progression. This was first shown in a study in which patients with metastatic disease that had progressed with a trastuzumab-based regimen were randomly assigned to receive capecitabine alone or capecitabine plus trastuzumab.
The Lancet Oncology , commentaire, 2015